KMDA Q3 2021 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena

KMDAKamada Ltd.

$495M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$23M-34.8% YoY

Gross Profit

$6M24.9% margin

Operating Income

-$804,000-3.5% margin

Net Income

-$845,000-3.7% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-5.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$134,000

Balance Sheet

Total Assets

$217M

Total Liabilities

$35M

Stockholders' Equity

$182M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$35M	-34.8%
Gross Profit	$6M	$15M	-61.3%
Operating Income	-$804,000	$8M	-110.4%
Net Income	-$845,000	$7M	-112.4%

Geographic Segments

UNITED STATES

$13M74%

Latin America

$2M10%

OtherForeignCountriesThreeMember

$1M6%

ISRAEL

$849,0005%

Asia

$734,0004%

OtherCountriesMember

$81,0000%